SOURCE: Healthcare Global

NORWICH, UNITED KINGDOM--(Marketwire - Feb 21, 2012) - In April 2011 researchers from IBM and the Institute of Bioengineering and Nanotechnology (IBN) announced that they had stumbled on "a nanomedicine breakthrough." They discovered a new type of polymer which was able to detect and destroy bacteria that is resistant to antibiotics and infectious diseases such as MRSA. It is now hoped the discovery will have the potential to revolutionise treatments for MRSA and other superbugs which are becoming increasingly common in hospitals and healthcare environments across the world.

If commercially manufactured, these biodegradable nanostructures could be injected directly into the body or applied topically to the skin, treating skin infections through consumer products like deodorant, soap and hand sanitizer, as well as being used to help heal wounds, tuberculosis and lung infections.

To get a more up-to-date picture of how the discovery and development of this innovative new technique is progressing, Healthcare Global caught up with Dr James Hedrick, an IBM research scientist, in its March issue.

To read this article in full, visit http://www.healthcareglobal.com or read the February issue Healthcare Global digital magazine.

About Healthcare Global

Healthcare Global is a pioneering digital media site for Healthcare professionals and executives responsible for all aspects of managing this environment. Healthcare Global covers solutions that enable global healthcare executives to improve the way they manage their operations. Healthcare Global is the industry-dedicated arm of the WDM Group. Founded in 2007 by entrepreneur Glen White, WDM Group retains a diversified portfolio of websites, magazines, mobile apps, daily news feeds and weekly e-newsletters that leverage technology to innovatively deliver high-quality content, analytical data, and industry news.

Healthcare Global is headquartered in San Diego, California, with additional offices in Boston, Toronto, Mumbai and Norwich, England. For more information, contact 760-827-7800 or visit http://www.healthcareglobal.com.

Read the original:
IBM and IBN Treating MRSA With Nanotechnology and Nanomedicine in February's Edition of Healthcare Global